Q-omics provides the consensus-scored NLRP6 profile across patient tissues and cancer cell-line models. NLRP6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, NLRP6 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, NLRP6 RNA expression shows 15,824 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where NLRP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRP6 survival associations across molecular data types. NLRP6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRP6 RNA expression–survival associations across cancer types. High NLRP6 expression shows unfavorable associations in UVM, but favorable associations in SKCM, KIRC, HNSC, LIHC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for NLRP6 RNA expression.
This table summarizes NLRP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NLRP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRP6 shows lower tumor expression in KICH, CHOL and KIRP and higher tumor expression in KIRC, BRCA and HNSC. The KIRC box plot shows higher NLRP6 RNA expression in tumor versus normal tissue (log2 FC = +1.129, t-test p < 0.001).
This table shows molecular features associated with NLRP6 in patient tissues and cancer cell lines. In patient samples, NLRP6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
